Literature DB >> 11435465

Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling.

S G Apasov1, M R Blackburn, R E Kellems, P T Smith, M V Sitkovsky.   

Abstract

Adenosine deaminase (ADA) deficiency in humans results in a severe combined immunodeficiency (SCID). This immunodeficiency is associated with severe disturbances in purine metabolism that are thought to mediate lymphotoxicity. The recent generation of ADA-deficient (ADA(-/-)) mice has enabled the in vivo examination of mechanisms that may underlie the SCID resulting from ADA deficiency. We demonstrate severe depletion of T and B lymphocytes and defects in T and B cell development in ADA(-/-) mice. T cell apoptosis was abundant in thymi of ADA(-/-) mice, but no increase in apoptosis was detected in the spleen and lymph nodes of these animals, suggesting that the defect is specific to developing thymocytes. Studies of mature T cells recovered from spleens of ADA(-/-) mice revealed that ADA deficiency is accompanied by TCR activation defects of T cells in vivo. Furthermore, ex vivo experiments on ADA(-/-) T cells demonstrated that elevated adenosine is responsible for this abnormal TCR signaling. These findings suggest that the metabolic disturbances seen in ADA(-/-) mice affect various signaling pathways that regulate thymocyte survival and function. Experiments with thymocytes ex vivo confirmed that ADA deficiency reduces tyrosine phosphorylation of TCR-associated signaling molecules and blocks TCR-triggered calcium increases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11435465      PMCID: PMC209335          DOI: 10.1172/JCI10360

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

Review 1.  Identification of dying cells--in situ staining.

Authors:  S A Ben-Sasson; Y Sherman; Y Gavrieli
Journal:  Methods Cell Biol       Date:  1995       Impact factor: 1.441

2.  Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c.

Authors:  X Liu; C N Kim; J Yang; R Jemmerson; X Wang
Journal:  Cell       Date:  1996-07-12       Impact factor: 41.582

Review 3.  Leukocyte protein tyrosine kinases: potential targets for drug discovery.

Authors:  J B Bolen; J S Brugge
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

4.  Effects of extracellular ATP and adenosine on different thymocyte subsets: possible role of ATP-gated channels and G protein-coupled purinergic receptor.

Authors:  S G Apasov; M Koshiba; T M Chused; M V Sitkovsky
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

5.  Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants.

Authors:  R H Buckley; R I Schiff; S E Schiff; M L Markert; L W Williams; T O Harville; J L Roberts; J M Puck
Journal:  J Pediatr       Date:  1997-03       Impact factor: 4.406

6.  Metabolic and immunologic consequences of limited adenosine deaminase expression in mice.

Authors:  M R Blackburn; S K Datta; M Wakamiya; B S Vartabedian; R E Kellems
Journal:  J Biol Chem       Date:  1996-06-21       Impact factor: 5.157

7.  Tissue-specific rescue suggests that placental adenosine deaminase is important for fetal development in mice.

Authors:  M R Blackburn; M Wakamiya; C T Caskey; R E Kellems
Journal:  J Biol Chem       Date:  1995-10-13       Impact factor: 5.157

8.  Interference with thymocyte differentiation by an inhibitor of S-adenosylhomocysteine hydrolase.

Authors:  P Benveniste; W Zhu; A Cohen
Journal:  J Immunol       Date:  1995-07-15       Impact factor: 5.422

9.  p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency.

Authors:  P Benveniste; A Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

10.  Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl.

Authors:  S J Martin; C P Reutelingsperger; A J McGahon; J A Rader; R C van Schie; D M LaFace; D R Green
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  45 in total

1.  A deficiency in nucleoside salvage impairs murine lymphocyte development, homeostasis, and survival.

Authors:  Onjee Choi; Dean A Heathcote; Ka-Kei Ho; Phillip J Müller; Hazim Ghani; Eric W-F Lam; Philip G Ashton-Rickardt; Sophie Rutschmann
Journal:  J Immunol       Date:  2012-03-09       Impact factor: 5.422

2.  IL-13 and adenosine: partners in a molecular dance?

Authors:  Gabriele Grünig
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

Review 3.  The molecular pathology of primary immunodeficiencies.

Authors:  Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2004-05       Impact factor: 5.568

Review 4.  Regulation of lymphocyte function by adenosine.

Authors:  Joel Linden; Caglar Cekic
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-07-05       Impact factor: 8.311

5.  Inhibition of Transient Receptor Potential Channel Mucolipin-1 (TRPML1) by Lysosomal Adenosine Involved in Severe Combined Immunodeficiency Diseases.

Authors:  Xi Zoë Zhong; Yuanjie Zou; Xue Sun; Gaofeng Dong; Qi Cao; Aditya Pandey; Jan K Rainey; Xiaojuan Zhu; Xian-Ping Dong
Journal:  J Biol Chem       Date:  2017-01-13       Impact factor: 5.157

6.  Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome.

Authors:  Olga Nikolajeva; Austen Worth; Rosie Hague; Nuria Martinez-Alier; Joanne Smart; Stuart Adams; E Graham Davies; H Bobby Gaspar
Journal:  J Clin Immunol       Date:  2015-04-15       Impact factor: 8.317

Review 7.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

8.  Comparison of elapegademase and pegademase in ADA-deficient patients and mice.

Authors:  L Murguia-Favela; W Min; R Loves; M Leon-Ponte; E Grunebaum
Journal:  Clin Exp Immunol       Date:  2020-02-09       Impact factor: 4.330

9.  Restoring balance to B cells in ADA deficiency.

Authors:  Eline T Luning Prak
Journal:  J Clin Invest       Date:  2012-05-24       Impact factor: 14.808

10.  Adenosine deaminase and 5'nucleotidase activities in peripheral blood T cells of multiple sclerosis patients.

Authors:  S Vivekanandhan; C C Soundararajan; M Tripathi; M C Maheshwari
Journal:  Neurochem Res       Date:  2005-04       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.